Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia

Focal adhesion kinase (FAK) promotes cancer cell growth and metastasis. We previously reported that FAK inhibition by the selective inhibitor VS-4718 exerted antileukemia activities in acute myeloid leukemia (AML). The mechanisms involved, and whether VS-4718 potentiates efficacy of other therapeutic agents, have not been investigated. Resistance to apoptosis inducted by the BCL-2 inhibitor ABT-199 (venetoclax) in AML is mediated by preexisting and ABT-199–induced overexpression of MCL-1 and BCL-XL. We observed that VS-4718 or silencing FAK with siRNA decreased MCL-1 and BCL-XL levels. Importantly, VS-4718 antagonized ABT-199–induced MCL-1 and BCL-XL. VS-4718 markedly synergized with ABT-199 to induce apoptosis in AML cells, including primary AML CD34+ cells and AML cells overexpressing MCL-1 or BCL-XL. In a patient-derived xenograft (PDX) model derived from a patient sample with NPM1/FLT3-ITD/TET2/DNMT3A/WT1 mutations and complex karyotype, VS-4718 statistically significantly reduced leukemia tissue infiltration and extended survival (72 vs. control 36 days, P = 0.0002), and only its combination with ABT-199 effectively decreased systemic leukemia tissue infiltration and circulating blasts, and prolonged survival (65.5 vs. control 36 days, P = 0.0119). Furthermore, the combination decreased NFκB signaling and induced the expression of IFN genes in vivo. The combination also markedly extended survival of a second PDX model developed from an aggressive, TP53-mutated complex karyotype AML sample. The data suggest that the combined inhibition of FAK and BCL-2 enhances antileukemia activity in AML at least in part by suppressing MCL-1 and BCL-XL and that this combination may be effective in AML with TP53 and other mutations, and thus benefit patients with high-risk AML.

[1]  W. Wierda,et al.  Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies , 2019, Drugs.

[2]  A. Letai,et al.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.

[3]  M. Konopleva,et al.  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.

[4]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[5]  R. Stone,et al.  A concise review of BCL-2 inhibition in acute myeloid leukemia , 2018, Expert review of hematology.

[6]  Elizabeth J. Osterlund,et al.  BCL-2 family proteins: changing partners in the dance towards death , 2017, Cell Death and Differentiation.

[7]  S. Cory,et al.  The BCL-2 arbiters of apoptosis and their growing role as cancer targets , 2017, Cell Death and Differentiation.

[8]  Marina Konopleva,et al.  Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. , 2017, Cancer cell.

[9]  R. Mesa,et al.  Combined venetoclax and alvocidib in acute myeloid leukemia , 2017, Oncotarget.

[10]  John Calvin Reed,et al.  Therapeutics targeting Bcl-2 in hematological malignancies. , 2017, The Biochemical journal.

[11]  Chenguang Wang,et al.  The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma , 2017, PloS one.

[12]  W. Tam,et al.  Inhibition of FAK kinase activity preferentially targets cancer stem cells. , 2017, Oncotarget.

[13]  L. Lam,et al.  Potential mechanisms of resistance to venetoclax and strategies to circumvent it , 2017, BMC Cancer.

[14]  S. Gore,et al.  Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings , 2017, Leukemia & lymphoma.

[15]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[16]  M. Konopleva,et al.  Pathways and mechanisms of venetoclax resistance , 2017, Leukemia & lymphoma.

[17]  K. Coombes,et al.  Focal Adhesion Kinase as a Potential Target in AML and MDS , 2017, Molecular Cancer Therapeutics.

[18]  R. Plummer,et al.  A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[20]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[21]  K. Wood,et al.  Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia , 2016, Scientific Reports.

[22]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[23]  A. Baldwin,et al.  The NF-κB Pathway and Cancer Stem Cells , 2016, Cells.

[24]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[25]  Jijun Fu,et al.  Phosphatidylinositol 3-Kinase/Akt Mediates Integrin Signaling To Control RNA Polymerase I Transcriptional Activity , 2016, Molecular and Cellular Biology.

[26]  Suzanne F. Jones,et al.  A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors , 2015, Investigational New Drugs.

[27]  T. Kurosu,et al.  FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia , 2015, Oncotarget.

[28]  P. Timpson,et al.  FAK signaling in human cancer as a target for therapeutics. , 2015, Pharmacology & therapeutics.

[29]  R. Cook,et al.  Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? , 2015, Oncotarget.

[30]  S. Mazumder,et al.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies , 2015, Cell Death and Disease.

[31]  L. Gordon,et al.  Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer. , 2015, Critical reviews in oncogenesis.

[32]  H. Martin,et al.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. , 2014, Cell reports.

[33]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[34]  D. Schlaepfer,et al.  FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.

[35]  Andrea I. McClatchey,et al.  Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship , 2014, Science Translational Medicine.

[36]  A. Letai,et al.  Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.

[37]  M. Hung,et al.  Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer , 2011, Front. Oncol..

[38]  G. López-Castejón,et al.  Understanding the mechanism of IL-1β secretion , 2011, Cytokine & growth factor reviews.

[39]  G. Mcmahon,et al.  PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments , 2010, Cancer biology & therapy.

[40]  A. Tichelli,et al.  Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia , 2010, Annals of Hematology.

[41]  Paolo Romano,et al.  Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines , 2008, Nucleic Acids Res..

[42]  Chunaram Choudhary,et al.  Activation mechanisms of STAT5 by oncogenic Flt3-ITD. , 2006, Blood.

[43]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[44]  B. Williams,et al.  Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis , 2003, Apoptosis.

[45]  W. Hiddemann,et al.  Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  E. Borden,et al.  Identification of X-linked Inhibitor of Apoptosis-associated Factor-1 as an Interferon-stimulated Gene That Augments TRAIL Apo2L-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[47]  M. Andreeff,et al.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. , 2002, Cancer research.

[48]  M. Fricová,et al.  High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. , 2002, Neoplasma.

[49]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.